ADVERTISEMENT
Tariff On Indian Pharma Will Raise Costs For US Buyers, Says Wockhardt's Khorakiwala
Speaking at the NDTV Profit Conclave, Wockhardt's founder and chairman explained that the Indian pharma industry supplies around 40% of the medicine that American consumers use.
18 Feb 2025, 02:16 PM IST 
From left, Tamanna Inamdar, executive editor NDTV Profit, Dipali Goenka, CEO and manaing director, Welspun Living Ltd., Habil Khorakiwala, founder chairman Wockhardt Group, Rajesh Sharma CEO, Kaynes Technology India Ltd. at NDTV Profit Conclave on Tuesday. (Photographer: Vishwanath Nair/NDTV Profit)
Habil Khorakiwala, founder chairman of Wockhardt Ltd., is not concerned about US President Donald Trump imposing tariffs on India, especially when it comes to the pharma sector. His rationale is simple. Any tariff imposed on Indian pharmaceutical products will be passed onto the US consumers. Speaking at the NDTV Profit Conclave on Tuesday, Khorakiwala explained that as far as Indian pharmaceutical industry is concerned, it is one of...
